Lead Product(s) : CDNF
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Nanoform
Deal Size : Undisclosed
Deal Type : Agreement
Nanoform and Herantis sign Biologics Proof of Concept Agreement
Details : Nanoform and Herantis have signed a letter of intent to collaborate to seek to enhance nasal drug delivery to the brain of Herantis’ CDNF and xCDNF therapies (Parkinson’s disease) using Nanoform’s proprietary biological nanoparticle technology.
Product Name : CDNF
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
December 17, 2020
Lead Product(s) : CDNF
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Nanoform
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : CDNF
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Herantis Pharma Plc Announces Topline Results of Phase 1-2 CDNF Trial
Details : Topline analysis confirms positive safety and tolerability of CDNF in advanced-stage Parkinson's disease patients, with encouraging biological responses.
Product Name : CDNF
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
February 25, 2020
Lead Product(s) : CDNF
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable